Interim analysis of the PARADISE study: Benefits of add-on peginterferon-α in NA-treated patients with CHB.
Jiang S, Guo S, Huang Y, Xu J, Li Y, Zeng Y, Guo Y, Ouyang L, Zhu C, Zhao W, Zhang Q, Guo Q, Xin H, Xie Q.
Jiang S, et al. Among authors: li y.
Antiviral Res. 2024 Jun;226:105892. doi: 10.1016/j.antiviral.2024.105892. Epub 2024 Apr 23.
Antiviral Res. 2024.
PMID: 38663455
Free article.
Clinical Trial.